New drug HLX48 enters first human trial for Hard-to-Treat cancers
NCT ID NCT07473726
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called HLX48 in 72 people with advanced or metastatic solid tumors that have not responded to standard treatments. HLX48 is designed to target two cancer-related proteins (EGFR and c-MET) and deliver a toxic payload directly to cancer cells. The main goals are to check safety, find the right dose, and see how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX48 (a bispecific antibody-drug conjugate targeting EGFR and c-MET)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 72 participants, focused on safety and dosing. It may not show strong anti-tumor effects, and side effects could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare St.Leonards
Saint Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University
North Ryde, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, 3199, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai General Hospital
Hongkou, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangzhou, 716099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
Contact Phone: •••-•••-•••• Email: •••••@•••••